leisure time -WSS

leisure time

author：comprehensive 2025-09-06 03:57:55 - browse：655

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： 'The boss' wants server deleted: New allegations emerge in Trump indictment

WSS

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Steward Health Care files for bankruptcy

Biden jokes that Republicans may impeach him because inflation is starting to cool down

How to improve immunocompromised access to mAb treatments

Telehealth startups turn to complex chronic diseases

An outrageous hospital charge: I paid $710 for an hour of babysitting

Wikipedia

leisure time

knowledge

In Memoriam: Notable people who died in 2023

Apple Watch's A

Drug repurposing or repositioning? The language matters

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Jerome Adams on the need for new antivirals for Covid

Telehealth startups turn to complex chronic diseases

Psychedelics group wrestles with new pharma identity

H5N1 bird flu: what we're starting to learn about infection in cows

focus

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Will biotech layoffs continue through 2023?

H5N1 bird flu: what we're starting to learn about infection in cows

Apple Watch's A

Alexander Hamilton and the argument for universal insurance

Making AI in medicine accessible to smaller, and rural hospitals

entertainment

Wikipedia

explore

focus